News

Pierre Billardon

Leading a Global Leader, with Pierre Billardon

By Jackie Wengrod | August 24, 2021

PODCAST EPISODE 294

Read More
FDA rejected Abicipar

A Year After FDA Rejected Abicipar, AbbVie Gives It Back to Molecular Partners

By Rich Kirkner | August 17, 2021

In the summer of 2020, shortly after the US Food and Drug Administration issued a negative Complete Response Letter to AbbVie and Molecular Partners, rejecting…

Read More

NIH Awards Amydis $3 Million Grant Award for Novel Amyloid Beta Retinal Tracer Applicable to CNS Diseases

By Conni Bergmann Koury | August 10, 2021

Amydis is developing novel small-molecule contrast agents that aim to enable the direct visualization of central nervous system (CNS) disease-related biomarkers in the retina. The…

Read More

Stem Cell-Engineered Implant for Geographic Atrophy Shows Promise, Long-Term Survival of Cells in Early Trial

By Conni Bergmann Koury | August 3, 2021

A number of companies are developing drug treatments for geographic atrophy, the result of advanced dry age-related macular degeneration (AMD), for which no approved treatments…

Read More

4DTM Goes It Alone After Roche Pulls Out of Gene Therapy Trials

By Karen Blum | July 20, 2021

In 2018, 4D Molecular Therapeutics announced it was expanding its 2015 research agreement with Roche to develop and commercialize multiple ophthalmology products. This summer, things…

Read More

Second Sight Gets a Double-Shot Boost Thanks to PO and NIH installment

By Rich Kirkner | July 13, 2021

Up until a few weeks ago, 2021 had been an up-and-down year for retinal prosthesis maker Second Sight Medical Products, but it recently got a…

Read More

Samsung Bioepis Brings Heat to Race for Anti-VEGF Biosimilars

By Rich Kirkner | July 6, 2021

South Korea-based Samsung Bioepis Co. has gained another leg up in the race for an anti-VEGF biosimilar to treat retinal diseases in the lucrative US…

Read More

Two Steps Forward for Clearside’s SCS Suprachoroidal Platform

By Rich Kirkner | June 28, 2021

The novel platform Clearside Biomedical is developing for delivering drugs to the back of the eye has taken two steps forward in recent weeks, with…

Read More

Heru Closes $30 Million Series A Round

By Karen Blum | June 23, 2021

Heru, developer of an artificial intelligence-powered vision diagnostics and augmentation software platform, gave its development program a boost when it closed a Series A financing…

Read More

Apellis Building on Its Platform with APL-2 for Geographic Atrophy

By Steve Lenier | June 8, 2021

Weeks after receiving Food and Drug Administration approval for its complement factor 3 (C3) inhibitor pegcetacoplan, now known as Empaveli, to treat adults who have…

Read More

Oxurion Nets a Fresh $36 Million, Names New CEO as Candidates Advance in Pipeline

By Karen Blum | June 2, 2021

Oxurion NV, the Brussels-based biopharmaceutical company formerly known as ThromboGenics, entered into a capital commitment agreement of up to $36 million (€30 million) with Negma…

Read More
OIS Digital Innovation Showcase

The Four Trends Driving the Digital Space

By Rich Kirkner | May 25, 2021

Money is pouring into digital health at a record clip – $6.7 billion in the first quarter this year, the investment firm Rock Health reports.…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.